WAVE Life Sciences (WVE) Highlights Growth Strategy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to WAVE Life Sciences (WVE) Highlights Growth Strategy

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

September 28, 2023 4:15 PM EDT

Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Waves best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK

WVE-006 industrys first-ever RNA editing clinical candidate on track for dosing in RestorAATion clinical trial in 4Q 2023 and first human proof-of-mechanism data in 2024

Advancing multiple, wholly owned RNA editing targets using correction and upregulation approaches; leveraging proprietary deep-learning model to unlock additional targets across the edit-verse

Wave platform chemistry enabling extra-hepatic delivery in RNA... More